Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

AstraZeneca divests Atacand’s European rights for $210m

pharmaceutical-technologyJuly 27, 2018

Tag: AstraZeneca , European

PharmaSources Customer Service